Peter Blume-Jensen, M.D., Ph.D., is Founder and President of Acrivon Therapeutics. He has extensive expertise in personalized oncology therapeutics and drug-tailored, efficacy-predictive biomarker discovery and development. Dr. Blume-Jensen has helped launch, lead, in-license and acquire novel oncology drug development programs at EMD Serono, Merck & Co. and Daiichi Sankyo. Prior to Acrivon, he served as Chief Scientific Officer at XTuit Pharmaceuticals, and before that at Metamark Genetics, where he led the establishment and launch of a novel, automated intact tissue protein-based prostate cancer test, ProMark, which is included under NCCN Guidelines. He serves on the scientific advisory boards of Veritas Genetics and the International Institute of Molecular Oncology (IIMO).